Neurotoxin selection is not commodity shopping. While all five FDA-cleared botulinum toxin Type A products (Botox, Dysport, Jeuveau, Daxxify, Xeomin) block acetylcholine at the neuromuscular junction, their formulations, diffusion profiles, onset kinetics, and duration claims differ meaningfully—and those differences drive both clinical outcomes and your per-unit cost basis. For a practice owner, the decision hinges on three overlapping questions: What onset and duration do your patients expect? What is your true cost per unit after rebates and loyalty programs? And which product mix maximizes both patient satisfaction and margin? This guide cuts through marketing claims and provides the framework to make that choice.